Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

INNOVATIVE PHARMACEUTICAL BIOTECH LIMITED
領航醫藥及生物科技有限公司
(Incorporated in the Cayman Islands and continued in Bermuda with limited liability)
(Stock Code: 399)

EXTENSION OF LONG STOP DATES

References are made to the announcement of the Company dated 15 July 2025 and 16 July 2025 (the "**Announcements**") in relation to the subscription of 60,000,000 shares and 30,000,000 shares of the Company by Zhang Biaobing and Chen Jing, respectively, at the subscription price of HK$0.3124 per subscription shares. Unless the context otherwise requires, capitalised terms used herein shall have the same meanings as defined in the Announcements.

SUBSCRIPTION AGREEMENT A

Pursuant to the Subscription Agreement A, if the condition precedent is not fulfilled by 5 August 2025, or such other time and date as may be agreed by Subscriber A and the Company in writing, all rights, obligations and liabilities of Subscriber A and the Company under Subscription Agreement A shall cease and determine and neither party shall have any claim against the other, save for any antecedent breaches of the terms thereof.

As additional time is required to fulfil the condition precedent set out in the Subscription Agreement A, on 5 August 2025, the Company has entered into an extension letter with Subscriber A to extend the long stop date from 5 August 2025 to 26 August 2025, or such other time and date as may be agreed by Subscriber A and the Company in writing.

Save for the above, all other terms and conditions of the Subscription Agreement A (as amended and supplemented by the Supplemental Agreement A) shall remain unchanged and continue in full force and effect.

SUBSCRIPTION AGREEMENT B

Pursuant to the Subscription Agreement B, if the condition precedent is not fulfilled by 5 August 2025, or such other time and date as may be agreed by Subscriber B and the Company in writing, all rights, obligations and liabilities of Subscriber B and the Company under Subscription Agreement B shall cease and determine and neither party shall have any claim against the other, save for any antecedent breaches of the terms thereof.

As additional time is required to fulfil the condition precedent set out in the Subscription Agreement B, on 5 August 2025, the Company has entered into an extension letter with Subscriber B to extend the long stop date from 5 August 2025 to 26 August 2025, or such other time and date as may be agreed by Subscriber B and the Company in writing.

Save for the above, all other terms and conditions of the Subscription Agreement B (as amended and supplemented by the Supplemental Agreement B) shall remain unchanged and continue in full force and effect.

By order of the Board
Innovative Pharmaceutical Biotech Limited
Yeung Yung
Chairman

Hong Kong, 5 August 2025

As at the date of this announcement, the Board comprises Dr. Yeung Yung (Chairman and executive Director), Mr. Gao Yuan Xing (executive Director), Mr. Tang Rong (executive Director), Ms. Qi Shujuan (executive Director), Dr. Long Fan (executive Director), Dr. Wu Ming (executive Director), Mr. Zhang Shen (executive Director), Mr. Zhang Yi (non-executive Director), Ms. Chen Weijun (independent non-executive Director), Mr. Wang Rongliang (independent non-executive Director), Mr. Chen Jinzhong (independent non-executive Director), Dr. Xia Tingkang, Tim (independent non-executive Director), and Ms. Sun Sizheng (independent non-executive Director).

Please also refer to the published version of this announcement on the Company's website: www.ipb.asia and www.irasia.com/listco/hk/ipb.